Highlights & History
| 1970's | Stanford Blood Center Opens Begin screening for Hepatitis B Begin providing HLA compatible platelets |
| 1980's | Begin providing CMV negative blood to
patients Begin surrogate testing for AIDS virus Join National Marrow Donor Program Begin screening for HTLV |
| 1990's | Begin screening for Hepatitis
C Begin confirmatory testing for HTLV-I/II Begin differential testing between HTLV-I and HTLV-II Begin researching what would later become the first FDA-approved cancer vaccine |
| 2000's | Begin West Nile NAT Begin Chagas Testing |
Our Mission
At Stanford Blood Center, we provide hope for the future: teaching tomorrow's leaders in transfusion medicine, researching to unlock mysteries inherent in blood, and connecting donors to patients every day.
A Brief History
Stanford Blood Center was created within the Department of Pathology at Stanford University School of Medicine in 1978. The Blood Center was created to meet the increasingly large and complex transfusion needs of Stanford Hospital and Lucile Salter Packard Children's Hospital at Stanford, and to perform research and teaching.
Milestones
The history of the Blood Center is replete with milestones in transfusion medicine, particularly in the areas of blood safety and compatibility testing.
- Stanford Blood Center was the first in the world to routinely
test for cytomegalovirus (CMV) and provide CMV negative blood for
immunocompromised transfusion recipients.
- Stanford Blood Center was among the first in the country to provide
HLA compatible platelets.
- In 1983, Stanford Blood Center was the first blood center
to screen for AIDS contaminated blood, using a surrogate test (T
lymphocyte phenotyping) two years before the AIDS virus antibody
test was developed.
- In 1987, Stanford Blood Center was the first in the country to
screen donors for HTLV-I, a virus believed to cause a form of adult
leukemia.
- In the early 1990's, Stanford Blood Center's founder and Medical Director, Edgar Engleman, MD, developed the methodology behind the first FDA approved cancer vaccine for advanced prostate cancer — a treatment that trains the body's own immune system to fight cancerous tumors. This treatment has the potential to fight other types of cancer as well.
- Currently we are among the few blood centers in the country to use a research test to differentiate between HTLV-I and HTLV-II.
These achievements represent the outcome of a close working relationship between research and clinical personnel, and the integration of the research labs with the Blood Center and Transfusion Service clinical programs.
Service and Diversity
Stanford Blood Center strives to maintain a standard of service excellence in meeting the needs of physicians, and our diverse donor and patient populations.
The Blood Center has developed a large Automated Blood Collection program, including Double Red Blood Cell collection and multiple plasma product collection, in response to the growing needs of hospital programs targeting oncology, bone marrow and solid organ transplant. We serve the second largest transfusion facility in the United States, with a wide array of specialized products and services.
Two histocompatibility labs were purchased from Stanford University Hospital in 1992 to complement the Blood Center HLA Laboratory and to meet growing transplant needs.
The Autologous (self-donation) and Designated Donations Department is dedicated to responding to the special needs of this group of donors. Stanford's Donor Services Department continues to adapt to the ever-changing needs of the ethnically diverse patient population. Community groups assist this effort through community education, seminars, and blood and tissue typing drives.
The Blood Center is proud of its history. We are committed to continuous
quality improvement through innovative management and an intramural
education program focusing on staff and management development.
